Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter,Randomized,Observational Blind Phase IIB Clinical Trial to Evaluate the Effectiveness,Immunogenicity and Safety of Two Doses of CoronaVac (Sinovac) Vaccine Against Two Doses of Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Adolescent (12-18 Years) Subjects

NCT05230940 is registered in ClinicalTrials.gov with Health Institutes of Turkey as lead sponsor.

NCT NCT05230940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05230940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter,Randomized,Observational Blind Phase IIB Clinical Trial to Evaluate the Effectiveness,Immunogenicity and Safety of Two Doses of CoronaVac (Sinovac) Vaccine Against Two Doses of Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Adolescent (12-18 Years) Subjects
Lead sponsor
Health Institutes of Turkey
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2022
Completion date
February 8, 2024
Enrollment
1 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection